Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

JOBS Act: Rule 506 Goes Into Effect Today

DC in Fall

Since Congress passed the Jumpstart our Business Startups (JOBS) Act last spring, there have been 39 IPOs in the biotech industry – and counting!  Today, another provision from the JOBS Act takes effect that will further enhance biotech capital formation. Pursuant to rules mandated by the JOBS Act, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D.  Rule 506 is a Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

Putting Patients First: Paving a Path to Useful CER

NPC_emailbanner_web

Comparative effectiveness research (CER) has the potential to improve health outcomes by helping people make better-informed decisions. But how do we know that CER will generate information that is useful? On September 30, in Washington, DC, you can be part of a conversation featuring a broad range of health care stakeholders—patients, providers, policymakers, payers, researchers, and those who fund research–by participating in an effort led by the National Health Council to create a framework to Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

FDA Consumer Update: Advances in Saving Lives with Blood

AB23475

Every two seconds in the U.S., someone needs a blood transfusion or blood product—people of all ages who are injured, need surgery or who are suffering from illness. The Food and Drug Administration’s primary responsibility with regard to blood and blood products is to assure the safety of patients who receive these life-saving products. In this interview, Richard Davey, M.D., director of the Division of Blood Applications, Office of Blood Research and Review at FDA Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Exploring New Solutions For Neglected Diseases in Developing Countries

SBIR Reauthorization Moves Forward

On Tuesday, BIO Ventures for Global Health (BVGH) announced the completion of the 30th research agreement as part of its partnership with the World Intellectual Property Organization (WIPO) to better enable drug companies to assist researchers in addressing infectious diseases worldwide. The partnership aims to accelerate development of drugs, diagnostics and vaccines for more than 1.5 billion people suffering from malaria, tuberculosis, and other neglected tropical diseases including dengue in developing nations. A recent publication in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

BioCentury This Week: Death & Taxes – Startups Need Fixes

BioCenturyTV

Vitae CEO Jeff Hatfield, Ernst & Young Partner Christopher Ohmes, and GPB Scientific CEO Michael Grisham will be discussing proposed tax changes that could spur billions of dollars in investment and create hundreds of thousands of jobs on BioCentury This Week airing Sunday September, 15 at 8:30am EST on WUSA-9. Biotech startups face death before taxes and unless investors are willing to finance years of losses, technologies that could save and improve lives are left Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,